Myocardial beta adrenoceptor density in primary and secondary left ventricular hypertrophy

L Choudhury1, S D Rosen, D C Lefroy

  • 1MRC Clinical Sciences Centre, Hammersmith Hospital, London, U.K.

European Heart Journal
|November 1, 1996
PubMed

Insights

Myocardial beta-adrenoceptor density is reduced in both hypertrophic cardiomyopathy and secondary left ventricular hypertrophy. This down-regulation occurs even when the heart

Area of Science:

  • Cardiology
  • Molecular Cardiology
  • Nuclear Cardiology

Background:

  • Myocardial beta-adrenoceptor density is reduced in hypertrophic cardiomyopathy (HCM) with preserved systolic function.
  • The presence of this down-regulation in secondary myocardial hypertrophy is not well-established.

Purpose of the Study:

  • To determine if beta-adrenoceptor down-regulation is unique to HCM or also occurs in secondary myocardial hypertrophy.
  • To compare beta-adrenoceptor density in patients with HCM, secondary left ventricular hypertrophy (LVH), and normal controls.

Main Methods:

  • Positron emission tomography (PET) with 11C-CGP-12177 was used to measure myocardial beta-adrenoceptor density.
  • Participants included 11 patients with HCM, 8 with secondary LVH (due to hypertension or aortic valve disease), and 18 controls.
  • Control groups were age-matched to patient groups to account for age-related changes in beta-adrenoceptor density.

Main Results:

  • Myocardial beta-adrenoceptor density was significantly lower in HCM patients (7.70 pmol/g) compared to matched controls (10.17 pmol/g).
  • Myocardial beta-adrenoceptor density was also significantly lower in secondary LVH patients (6.35 pmol/g) compared to matched controls (9.16 pmol/g).
  • Plasma catecholamine levels (noradrenaline and adrenaline) did not correlate with beta-adrenoceptor density in either patient group.

Conclusions:

  • Myocardial beta-adrenoceptor density is comparably decreased in both primary (HCM) and secondary left ventricular hypertrophy.
  • This down-regulation occurs despite preserved left ventricular systolic function in both conditions.
  • The findings suggest a common mechanism of beta-adrenoceptor alteration in different forms of left ventricular hypertrophy.
Abstract

Related Concept Videos

Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...